Royalty Pharma’s first quarter results surpassed Wall Street’s revenue and adjusted EBITDA expectations, driven by robust growth across its diversified royalty portfolio and increased capital deployment. Management attributed these results to double-digit gains in recurring royalty receipts and several new investments in therapies with significant commercial potential. CEO Pablo Legorreta emphasized the impact of recent clinical successes and portfolio expansion, noting, “We delivered 10% growth in portfolio receipts and 13% growth in royalty receipts, driven by the strength of our diversified portfolio.”

Is now the time to buy RPRX? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Royalty Pharma’s Q1 Earnings Call

• Hardik Parikh (JPMorgan): Asked about how much of Royalty Pharma’s 2030 portfolio receipt target is supported by current assets. CFO Terrance Coyne said they are confident in exceeding the target, citing strong portfolio developments but did not give specific asset breakdowns.
• Michael Nedelcovych (TD Cowen): Inquired about leverage after higher capital deployment and the ability to add royalty investments to ramping products. Coyne emphasized low leverage and ample capital capacity, while EVP Marshall Urist explained that additional capital deployment depends on partner options and product milestones.
• Jason Gerberry (Bank of America): Sought clarity on managing global launch value risk under new pricing policies and differences in IRR expectations for co-funding vs. traditional royalties. Urist noted they model a range of risk scenarios and maintain consistent return expectations across investment structures.
• Nick Jennings (Goldman Sachs): Asked about portfolio mix changes from increased R&D co-funding and China market progress. Chairman Chris Hite explained the company remains disciplined but expects a greater proportion of development-stage assets and highlighted recent platform-building efforts in China.
• Terence Flynn (Morgan Stanley): Questioned the impact of AI investments on deal flow and the J&J DUET data’s implications for Tremfya royalties. CEO Pablo Legorreta described AI as a key differentiator for forecasting and diligence, and Urist clarified that new royalties from the J&J partnership are incremental to legacy Tremfya royalties.

Catalysts in Upcoming Quarters

In coming quarters, the StockStory team will watch (1) progress on pivotal trial readouts and regulatory approvals for late-stage assets like daraxonrasib and Myqorzo, (2) continued deployment of capital into R&D co-funding and new royalty acquisitions, and (3) early signs of royalty revenue from recent product launches. We will also monitor any shifts in competitive dynamics and policy risks impacting royalty valuations.

Royalty Pharma currently trades at $52.03, up from $50.44 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).

The Best Stocks for High-Quality Investors

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.